Biosynexus

BioSynexus, located in Gaithersburg, MD, is dedicated to transforming the prevention and treatment of bacterial infections, with a particular emphasis on staphylococcal infections in very low birth weight infants. The company focuses on developing innovative, antibody-based, and enzymatic therapies to protect the most vulnerable populations in neonatal intensive care units (NICUs).

With a mission to combat antibiotic-resistant infections, BioSynexus is advancing solutions such as Pagibaximab, Lysostaphin, and Nisin, each targeting resistant strains of Staphylococcus aureus effectively and safely. Their efforts are aimed at reducing neonatal mortality and healthcare costs associated with recurrent infections while supporting global initiatives against antimicrobial resistance.

Generated from the website